1-3 of 3
Tomi K. Sawyer, PhD
Close
Sort by
Journal Articles

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

Mohammad Azam, PhD, William C. Shakespeare, PhD, Chester Metcalf, PhD, Yihan Wang, PhD, Raji Sunderamoorthi, PhD, Xiaotan Zhu, PhD, Wei-Sheng Huang, PhD, Dong Zou, PhD, Mathew Thomas, PhD, Jan Romero, PhD, Jeff Keats, PhD, Qihang Xu, PhD, David Dalgarno, PhD, Tim Clackson, PhD, Tomi K. Sawyer, PhD, George Q. Daley, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2181.
https://doi.org/10.1182/blood.V108.11.2181.2181
Published: 2006
Journal Articles

BCR-ABL Kinase Dynamics and Drug Resistance.

Mohammad Azam, PhD, Valentina Nardi, MD, William C. Shakespear, PhD, Robert R. Latek, PhD, Darren Veach, PhD, Bernard Clarckson, PhD, Regine Bohacheck, PhD, Tomi K. Sawyer, PhD, George Q. Daley, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1996.
https://doi.org/10.1182/blood.V106.11.1996.1996
Published: 2005
Journal Articles

A Potent Src/Abl Kinase Inhibitor (Ap23464) Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by Flt3-Itd Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an Abl-Independent Mechanism.

Jukka Kanerva, MD, PhD, Ogonna Nwawka, BS, Kevin Hwang, William C. Shakespeare, PhD, Chester A. Metcalf, III, PhD, Tomi K. Sawyer, PhD, Camille L. Bedrosian, MD, Seth J. Corey, MD
Journal: Blood
Blood (2004) 104 (11): 4479.
https://doi.org/10.1182/blood.V104.11.4479.4479
Published: 2004